Our findings provide important insights into the role of TSP-1 in context of NAFLD/NASH and TSP-1 may be a target of interest to develop anti-fibrotic therapeutics for NAFLD/NASH. This evidence concerns the gene THBS1 and metabolic dysfunction-associated steatohepatitis.